Clinical Trials
202 trialsDNAmetCRB
Istituto Ortopedico Rizzoli
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma
H. Lee Moffitt Cancer Center and Research Institute
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company
A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma
St. Jude Children's Research Hospital
OSE
Gustave Roussy, Cancer Campus, Grand Paris
Diffusion Weighted Magnetic Resonance in Imaging Younger Patients With Newly Diagnosed Bone or Soft Tissue Sarcomas
St. Jude Children's Research Hospital
Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma
National Cancer Institute (NCI)
IACE-OS
Shanghai 6th People's Hospital
PEMBROSARC
Institut Bergonié
BOOST
University of Minnesota
Molecular-Guided Therapy for Childhood Cancer
Milton S. Hershey Medical Center
AMLAS
University of Milano Bicocca
PRIMHADRON
Hospices Civils de Lyon
Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes
M.D. Anderson Cancer Center
METZOLIMOS
Institut Bergonié
Collecting and Storing Tissue From Young Patients With Cancer
Children's Oncology Group
Onco-QoL
Istituto Ortopedico Rizzoli
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors
Children's National Research Institute
Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors
Children's National Research Institute
ROOT
Taproot Health
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Nab-paclitaxel in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors
Emory University
Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors
Children's Oncology Group
ImmunoSarc
Grupo Espanol de Investigacion en Sarcomas
OAIE
Peking University People's Hospital
A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma
Eisai Inc.
Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors
Children's Oncology Group
A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors
Hutchmed
ISG/OS-2
Italian Sarcoma Group
A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
National Institutes of Health Clinical Center (CC)
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Memorial Sloan Kettering Cancer Center
Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
National Cancer Institute (NCI)
Vaccine Therapy in Treating Patients With Metastatic Cancer
National Cancer Institute (NCI)
Accuracy of Deep-learning Algorithm for Detection and Risk Stratification of Lung Nodules
Chinese University of Hong Kong
Perioperative Use of Tranexamic (TXA) in Bone Tumor Surgery Will Change in Blood Loss and Transfusion Requirements.
Children's Cancer Hospital Egypt 57357
ASCR
Washington University School of Medicine
Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma
Children's Oncology Group
Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance
Peking University People's Hospital
Osteosarcoma
Stanford University
PICaSO-ES
University Health Network, Toronto
Oncological and Functional Outcomes in Lower Limb Osteosarcoma Pediatric Patient
First Affiliated Hospital, Sun Yat-Sen University
Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy
Children's Oncology Group
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
Sarcoma Alliance for Research through Collaboration
Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma
National Cancer Institute (NCI)